tiprankstipranks
Bioextrax AB (SE:BIOEX)
:BIOEX

Bioextrax AB (BIOEX) AI Stock Analysis

Compare
0 Followers

Top Page

SE:BIOEX

Bioextrax AB

(BIOEX)

Select Model
Select Model
Select Model
Neutral 52 (OpenAI - 5.2)
Rating:52Neutral
Price Target:
kr2.50
▼(-21.63% Downside)
Action:ReiteratedDate:02/20/26
The score is held back primarily by weak financial performance (persistent losses, negative gross profit in most years, and ongoing/free cash flow burn that worsened in 2025), with only the debt-free balance sheet offering meaningful support. Technicals are a key positive (price above major moving averages with positive MACD and RSI), but valuation is constrained by negative earnings (negative P/E) and no available dividend yield.
Positive Factors
Debt-free balance sheet
A zero-debt balance sheet materially reduces refinancing and interest-rate risk over the medium term, giving the company structural financial flexibility. This conservatism supports continued R&D and scaling efforts without immediate interest burden, lengthening runway despite operating losses.
Negative Factors
Structural unprofitability
Consistently negative gross and operating results signal that current revenues do not cover core production and operating costs. Over the medium term, persistent losses erode equity, limit reinvestment capacity, and constrain ability to build durable commercial scale without a sustained profitability turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt balance sheet materially reduces refinancing and interest-rate risk over the medium term, giving the company structural financial flexibility. This conservatism supports continued R&D and scaling efforts without immediate interest burden, lengthening runway despite operating losses.
Read all positive factors

Bioextrax AB (BIOEX) vs. iShares MSCI Sweden ETF (EWD)

Bioextrax AB Business Overview & Revenue Model

Company Description
Bioextrax AB (BIOEX) is a Swedish biotechnology company that focuses on developing and commercializing environmentally sustainable technologies for converting waste materials into valuable products. The company operates in the sectors of bio-based...
How the Company Makes Money
null...

Bioextrax AB Financial Statement Overview

Summary
Financial quality is weak: revenue is very small and declining in 2024–2025, profitability is structurally negative (negative gross profit in most years and deeply negative operating/net results), and operating/free cash flow are consistently negative with an accelerating cash burn in 2025. The main offsetting strength is a conservatively financed balance sheet with zero reported debt, but equity is shrinking from ongoing losses.
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue757.00K515.00K2.06M395.00K275.76K
Gross Profit-18.37M-915.00K718.00K-18.64M-11.29M
EBITDA-17.24M-16.18M-20.65M-18.19M-10.18M
Net Income-17.70M-17.34M-21.51M-18.67M-10.53M
Balance Sheet
Total Assets24.73M29.00M22.52M37.92M12.64M
Cash, Cash Equivalents and Short-Term Investments3.93M17.27M13.40M27.53M8.98M
Total Debt0.000.000.000.000.00
Total Liabilities3.51M2.94M1.98M6.15M5.14M
Stockholders Equity21.21M26.06M20.54M31.77M7.50M
Cash Flow
Free Cash Flow-26.20M-18.99M-24.41M-24.38M-9.45M
Operating Cash Flow-26.05M-18.78M-23.31M-17.60M-8.48M
Investing Cash Flow-152.00K-215.00K-1.10M-6.78M-975.13K
Financing Cash Flow12.86M22.86M10.28M42.94M16.38M

Bioextrax AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.19
Price Trends
50DMA
2.65
Negative
100DMA
2.38
Positive
200DMA
2.79
Negative
Market Momentum
MACD
-0.05
Positive
RSI
43.22
Neutral
STOCH
43.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Negative. The current price of 3.19 is above the 20-day moving average (MA) of 2.76, above the 50-day MA of 2.65, and above the 200-day MA of 2.79, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.22 is Neutral, neither overbought nor oversold. The STOCH value of 43.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOEX.

Bioextrax AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
54
Neutral
kr124.85M-30.10-1.58%2.70%85.94%
53
Neutral
kr108.81M-13.81-17.60%-27.29%72.72%
52
Neutral
kr129.66M-6.27-94.54%-27.18%33.32%
49
Neutral
kr41.81M-2.71-25.32%
47
Neutral
kr110.77M22.145.40%8.54%-4.76%
44
Neutral
kr306.82M-2.12-20.69%-79.18%-257.25%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:BIOEX
Bioextrax AB
2.80
0.35
14.38%
SE:SES
Scandinavian Enviro Systems AB
0.28
-1.10
-79.74%
SE:AXOLOT
Axolot Solutions Holding AB
0.34
-0.17
-33.40%
SE:LEVEL
Nordic LEVEL Group AB Class B
0.59
-0.08
-11.34%
SE:CIRCHE
CirChem AB
1.04
-1.96
-65.33%
SE:CLEM
Clemondo Group AB
8.00
-0.60
-6.98%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 20, 2026